217 related articles for article (PubMed ID: 33086743)
1. In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity.
Matalińska J; Lipiński PFJ; Kosson P; Kosińska K; Misicka A
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086743
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist - neurokinin-1 antagonist peptidomimetics.
Guillemyn K; Kleczkowska P; Lesniak A; Dyniewicz J; Van der Poorten O; Van den Eynde I; Keresztes A; Varga E; Lai J; Porreca F; Chung NN; Lemieux C; Mika J; Rojewska E; Makuch W; Van Duppen J; Przewlocka B; Vanden Broeck J; Lipkowski AW; Schiller PW; Tourwé D; Ballet S
Eur J Med Chem; 2015 Mar; 92():64-77. PubMed ID: 25544687
[TBL] [Abstract][Full Text] [Related]
3. In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist-neurokinin 1 receptor antagonist chimera.
Guillemyn K; Kleczkowska P; Novoa A; Vandormael B; Van den Eynde I; Kosson P; Asim MF; Schiller PW; Spetea M; Lipkowski AW; Tourwé D; Ballet S
Mol Brain; 2012 Jan; 5():4. PubMed ID: 22289619
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Pharmacological Evaluation of Hybrids Targeting Opioid and Neurokinin Receptors.
Wtorek K; Adamska-Bartłomiejczyk A; Piekielna-Ciesielska J; Ferrari F; Ruzza C; Kluczyk A; Piasecka-Zelga J; Calo' G; Janecka A
Molecules; 2019 Dec; 24(24):. PubMed ID: 31817441
[TBL] [Abstract][Full Text] [Related]
5. Dual Alleviation of Acute and Neuropathic Pain by Fused Opioid Agonist-Neurokinin 1 Antagonist Peptidomimetics.
Betti C; Starnowska J; Mika J; Dyniewicz J; Frankiewicz L; Novoa A; Bochynska M; Keresztes A; Kosson P; Makuch W; Van Duppen J; Chung NN; Vanden Broeck J; Lipkowski AW; Schiller PW; Janssens F; Ceusters M; Sommen F; Meert T; Przewlocka B; Tourwé D; Ballet S
ACS Med Chem Lett; 2015 Dec; 6(12):1209-14. PubMed ID: 26713106
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.
Giri AK; Apostol CR; Wang Y; Forte BL; Largent-Milnes TM; Davis P; Rankin D; Molnar G; Olson KM; Porreca F; Vanderah TW; Hruby VJ
J Med Chem; 2015 Nov; 58(21):8573-83. PubMed ID: 26465170
[TBL] [Abstract][Full Text] [Related]
8. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
9. MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: a novel dual-acting mu- and kappa-opioid agonist with potent antinociceptive and weak rewarding effects in mice.
Matsumoto K; Takayama H; Narita M; Nakamura A; Suzuki M; Suzuki T; Murayama T; Wongseripipatana S; Misawa K; Kitajima M; Tashima K; Horie S
Neuropharmacology; 2008 Aug; 55(2):154-65. PubMed ID: 18550129
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
[TBL] [Abstract][Full Text] [Related]
11. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.
Yadlapalli JSK; Ford BM; Ketkar A; Wan A; Penthala NR; Eoff RL; Prather PL; Dobretsov M; Crooks PA
Pharmacol Res; 2016 Nov; 113(Pt A):335-347. PubMed ID: 27637375
[TBL] [Abstract][Full Text] [Related]
12. Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation.
Zhang T; Han Z; Shi X; Zhao W; Wang Z; Zhang R; Xu B; Zhang M; Zhang Q; Xiao J; Zhu H; Zheng T; Fang Q
Bioorg Med Chem; 2019 Feb; 27(4):630-643. PubMed ID: 30626554
[TBL] [Abstract][Full Text] [Related]
13. Genetic and pharmacological antagonism of NK
Sandweiss AJ; McIntosh MI; Moutal A; Davidson-Knapp R; Hu J; Giri AK; Yamamoto T; Hruby VJ; Khanna R; Largent-Milnes TM; Vanderah TW
Mol Psychiatry; 2018 Aug; 23(8):1745-1755. PubMed ID: 28485408
[TBL] [Abstract][Full Text] [Related]
14. Antinociceptive effects of two deltorphins analogs in the tail-immersion test in rats.
Kotlinska JH; Gibula-Bruzda E; Witkowska E; Chung NN; Schiller PW; Izdebski J
Peptides; 2013 Jan; 39():103-10. PubMed ID: 23183627
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward.
Mannangatti P; Sundaramurthy S; Ramamoorthy S; Jayanthi LD
Psychopharmacology (Berl); 2017 Feb; 234(4):695-705. PubMed ID: 28013351
[TBL] [Abstract][Full Text] [Related]
16. 14-O-Methylmorphine: A Novel Selective Mu-Opioid Receptor Agonist with High Efficacy and Affinity.
Zádor F; Balogh M; Váradi A; Zádori ZS; Király K; Szűcs E; Varga B; Lázár B; Hosztafi S; Riba P; Benyhe S; Fürst S; Al-Khrasani M
Eur J Pharmacol; 2017 Nov; 814():264-273. PubMed ID: 28864212
[TBL] [Abstract][Full Text] [Related]
17. A new potent analgesic agent with reduced liability to produce morphine tolerance.
Kiraly K; Caputi FF; Hanuska A; Kató E; Balogh M; Köles L; Palmisano M; Riba P; Hosztafi S; Romualdi P; Candeletti S; Ferdinandy P; Fürst S; Al-Khrasani M
Brain Res Bull; 2015 Aug; 117():32-8. PubMed ID: 26235542
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S
J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286
[TBL] [Abstract][Full Text] [Related]
19. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.
Bilsky EJ; Inturrisi CE; Sadée W; Hruby VJ; Porreca F
Pain; 1996 Dec; 68(2-3):229-37. PubMed ID: 9121809
[TBL] [Abstract][Full Text] [Related]
20. Antinociceptive and Cytotoxic Activity of Opioid Peptides with Hydrazone and Hydrazide Moieties at the C-Terminus.
Dyniewicz J; Lipiński PFJ; Kosson P; Bochyńska-Czyż M; Matalińska J; Misicka A
Molecules; 2020 Jul; 25(15):. PubMed ID: 32731576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
